At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 134 enrolled
Drug / intervention
exenatidedrug
Likely dose
exenatide 2.0mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin
In Brief
A Phase 3 clinical trial evaluating exenatide for Type 2 Diabetes. Completed, enrolled 134 participants across 26 sites in 5 countries.
Detailed Summary
This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesCanada, Mexico, Romania, South Africa, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartOct 2008
Primary CompletionJul 2009
Study CompletionNov 2009
TodayJul 2026
First PostedSep 17, 2008
Enrollment StartOct 1, 2008
Primary CompletionJul 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.8 years ago
Interventions
exenatidedrug
subcutaneous injection, 2.0mcg, once weekly